Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22+ Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic Leukemia | Journal of Clinical Oncology

PURPOSEThe use of inotuzumab ozogamicin (InO), a conjugated anti-CD22 monoclonal antibody, is becoming a promising frontline treatment for older patients with ALL.PATIENTS AND METHODSEWALL-INO is an open-label prospective multicenter phase II trial (…The EWALL-INO study demonstrates high efficacy and low toxicity in nonpreviously treated older patients with B-ALL.

Read the full article here

Source: ascopubs.org

Categories: Oncologists1, General Medicine News

Tags: Chemotherapy,Bcell,Leukemia,leusm

Tweets with this article

ASCO Publications

Inotuzumab Ozogamicin and Low-Intensity #Chemotherapy in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome-Negative #Bcell Precursor Acute Lymphoblastic #Leukemia: https://t.co/cjuqHPA6i2 #leusm

Neutrophil extracellular traps promote pre-metastatic niche formation in the omentum by expanding innate-like B cells that express IL-10

Lee et al. show that neutrophil extracellular traps (NETs) establish the pre-metastatic niche in the omentum by recruiting innate-like B cells and eliciting IL-10 production in…

Cancer Cell January 3, 2025

Unlocking the Potential of Patient Navigation: New CPT Codes Pave the Way for Enhanced Oncology Care

Explore the 2024 CPT codes for oncology patient navigation and how pharma can support improved patient outcomes.

john doe 5 January 3, 2025

Collection Details : Oncology Times

Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care

Oncology Times January 3, 2025

Real-World OS Outcomes Are Similar for Frontline CDK4/6 Inhibitor Combos in HR+, HER2– Breast Cancer

Retrospective data showed there was no OS difference between 3 frontline CDK4/6 inhibitor combos in HR-positive breast cancer.

OncLive.com January 3, 2025

New-Onset Diabetes and Pancreatic Cancer: An Important Link

Pancreatic cancer is a tough disease to catch early because it doesn’t always cause clear symptoms right away. Still, noticing changes in your body can…

Fox Chase Cancer Center January 2, 2025

Cusnir Explores Impact of ARANOTE Data on ARPI Plus ADT Use in mHSPC

During an in-person Community Case Forum event in Miami, Florida, Mike Cusnir, MD, discussed the ARANOTE study outcomes presented at ESMO 2024 and how they…

Targeted Oncology January 2, 2025

The Evolving Role of ctDNA in Guiding Adjuvant Chemotherapy Decisions in CRC: Insights from Stacey A. Cohen, MD

Stacey A. Cohen, MD, discusses insights into the evolving role of circulating tumor DNA in clinical decision-making for patients with colorectal cancer.

OncLive.com January 2, 2025

FDA Grants Priority Review to Avutometinib/Defactinib Combo in KRAS+ Ovarian Cancer

The FDA accepted and granted priority review to an NDA for avutometinib plus defactinib in recurrent KRAS-mutated low-grade serous ovarian cancer.

Targeted Oncology January 2, 2025

Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer

Maurice Pérol, MD, presents a pooled analysis of two pivotal Phase 2 trials assessing the efficacy and safety of taletrectinib in patients with advanced ROS1+…

OncLive.com January 2, 2025

Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial

These long-term results support METex14 as a targetable oncogenic driver in NSCLC and add to the evidence supporting capmatinib as a targeted treatment option for…

The Lancet Oncology January 2, 2025

Related Articles